Ho et al 1 raise the important issue of the risk of EBVassociated lymphoproliferation (PTLD) following reducedintensity conditioning and whether patients undergoing these procedures should be routinely screened for EBV load following transplantation as a means of targeting those at greatest risk for their development. As they point out, T cell depletion is a risk factor for the development of PTLD, although the combined T and B cell depletion mediated by CAMPATH-1H (alemtuzumab) appears to be associated with a somewhat reduced risk compared to methods that selectively deplete T cells. 2, 3 However, T cell depleted reduced intensity regimens that also incorporate fludarabine can be associated with profound delays in reconstitution of antigen-specific immunity, 4 reflected in a particularly high incidence of CMV reactivation. 5 We have performed 100 reduced-intensity allografts (57 HLAmatched related, 34 HLA-matched and nine mismatched unrelated) using a conditioning protocol incorporating alemtuzumab 100 mg, fludarabine 150 mg/m 2 and melphalan 140 mg/m 2 . 6 The 100 day mortality was 13%. There were two cases of PTLD (2.3%) in the group of 87 patients who survived beyond the period historically associated with the highest risk of PTLD. The first was in a 44-year-old female transplanted for high-grade non-Hodgkin's lymphoma (NHL) from a fully HLA-matched unrelated donor. A tonsillar biopsy performed on day 147 confirmed the diagnosis (a high grade B cell infiltrate strongly positive for EBV LMP1 and with 490% Ki67 positivity). Rapid neurological deterioration occurred despite rituximab therapy and multiorgan involvement was revealed at post mortem. The second was in a 23-year-old male transplanted for transformed low-grade NHL from an HLA-identical sibling. The diagnosis was confirmed on a mesenteric lymph node biopsy performed on day 73 following the development of progressive respiratory impairment and demonstration of abdominal lymphadenopathy. Treatment with rituximab combined with unselected donor lymphocytes (1 Â 10 6 CD3+ T cells/kg) resulted in resolution of the PTLD and the patient remains well with 206 days follow-up post-transplantation.
Two more patients developed PTLD following administration of antithymocyte globulin (ATG) for steroidresistant graft-versus-host disease (GVHD) occurring after donor lymphocyte infusions (DLI) given for disease progression. The treatment of acute GVHD with T cell depleting antibodies is a recognised risk factor for PTLD and was reported to be associated with a 43.2-fold relative risk in a study of 18 014 patients from the IBMTR registry and Seattle. 3, 7 Both of our patients received DLI from HLA-identical siblings (day 250 and day 515). One was a 46-year-old male with relapsed Hodgkin's lymphoma and the other was a 53-year-old male with multiple myeloma. Both manifested as deterioration of liver function and increased diarrhoea following an initial improvement of biopsy-proven GVHD, and in both cases the diagnosis was made at post mortem. A total of eight patients have received ATG for GVHD following DLI with this reducedintensity regimen. The incidence in this group (25%) therefore seems particularly high.
Overall, our data suggest that the risk of development of PTLD following reduced-intensity transplantation incorporating alemtuzumab appears to be comparable with that following conventional allogeneic transplantation, although we agree with Ho et al that the true risk will only become apparent with the availability of data on larger groups of patients. While quantification of viral load has been shown to correlate with the development of PTLD following T cell depleted myeloablative transplantation by a number of groups, 8 recipients of unmanipulated grafts have been documented to have increases in EBV-DNA levels without developing PTLD. 9 Similar studies following reduced-intensity transplantation will be required in order to confirm the predictive value in this setting. The risk of GVHD in the absence of DLI appears very low with alemtuzumab-containing regimens, and whether the incidence of PTLD in this setting is sufficient to warrant routine viral load estimation in all patients remains a matter of institutional choice. For those not currently monitoring patients following conventional allogeneic transplantation, there seems to be little direct evidence to suggest that these procedures need to be routinely instituted in the reduced intensity setting, with the caveat that there must be a low threshold for testing if any clinical suspicion arises. However, our data do support a significantly increased risk associated with ATG usage for the treatment of GVHD, even if this occurs at much later time points following transplantation, and we would suggest that in this group routine monitoring should be performed, particularly as adoptive cellular therapy is likely to be relatively contraindicated or ineffectual in this setting and early administration of anti-CD20 monoclonal antibody may be the best therapeutic option. 
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